A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
← catalyst calendarSponsored by Seagen, a wholly owned subsidiary of Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
120actual
Sites
96
Countries
Australia, Canada, Italy +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-14 | actual | When the study began enrolling |
| Primary completion | 2026-03-27 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-05-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-08-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Carcinoma, Non-Small-Cell Lung
- Ovarian Neoplasms
- Endometrial Neoplasms
- Head and Neck Neoplasms
Intervention
- Drug: disitamab vedotin — also filed as RC48, RC48-ADC
Primary outcome
what the primary-completion date above is the date OFConfirmed Objective Response Rate (ORR) per Response Evaluation in Solid Tumors version 1.1 (RECIST v1.1) by investigator assessment
measured Approximately 3 years
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed